COX-2 expression in ovarian cancer: an updated meta-analysis
PDF | HTML | How to cite
Metrics: PDF 1244 views | HTML 3064 views | ?
Haiming Sun1,2, Xuelong Zhang1, Donglin Sun1, Xueyuan Jia1, Lidan Xu1, Yuandong Qiao1 and Yan Jin1
1Laboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China
2National Human Genome Research Institute, National Institutes of Health, Baltimore, MD 21224, USA
Yan Jin, email: [email protected].
Keywords: COX-2, ovarian cancer, meta-analysis, prognosis
Received: February 24, 2017 Accepted: July 12, 2017 Published: October 04, 2017
The prognostic role of COX-2 expression in ovarian cancer patients has been studied for years, while results remain controversial. Thus we performed a meta-analysis to evaluate the prognostic impact of COX-2 expression on survival of ovarian cancer patients. The databases PubMed, Embase and CNKI were searched. Summary hazard ratio (HR) and 95% confidence intervals (CIs) were calculated to analyze the correlations between COX-2 expression and overall survival (OS), and disease-free survival (DFS). A total of 1,867 patients from 18 studies were enrolled in the final analysis. The results showed that patients with higher COX-2 expression had a poor OS (HR: 1.48; 95% CI: 1.19-1.85) and DFS (HR: 1.81, 95% CI: 1.28-2.55). Subgroup analysis showed that there had significant associations between COX-2 expression and survival rate in most of the subgroups. Furthermore, there were significant associations between COX-2 expression and several clinical parameters such as FIGO stage, histological type and age. These results showed the patients with higher COX-2 expression had a significantly poorer survival rate, COX-2 expression had the potential to be a prognostic marker of ovarian cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.